Increased antitumor capability of fiber-modified adenoviral vector armed with TRAIL against bladder cancers

Molecular and Cellular Biochemistry

Volumn 353, Issue 1-2, 2011, Pages 93-99

  Zhao, Youguang ^a   Li, Ying ^a   Wang, Qingtang ^a   Wang, Liang ^a   Yang, Hang ^a   Li, Mingli ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Ad35; Adenoviral vector; Biological therapy; Bladder cancer; Fiber modification; Gene therapy; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; MEMBRANE COFACTOR PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER GROWTH; CELL SURFACE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE VECTOR; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; TARGET CELL; TRANSGENE; TUMOR XENOGRAFT; VIRUS INFECTION;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD46; CAPSID PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTORS, VIRUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR BURDEN; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 79959281823     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-011-0778-5     Document Type: Article

References (27)

1. Jacobs BL, Lee CT, Montie JE (2010) Bladder cancer in 2010: how far have we come? CA Cancer J Clin 60:244-272
2. Voutsinas GE, Stravopodis DJ (2009) Molecular targeting and gene delivery in bladder cancer therapy. J BUON 14:S69-S78
3. Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P et al (2003) Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 21:2247-2253 (Pubitemid 46621859)
4. Kuball J, Wen SF, Leissner J, Atkins D, Meinhardt P, Quijano E et al (2002) Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 20:957-965 (Pubitemid 34141838)
5. Malmström PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A et al (2010) AdCD40L immunogene therapy for bladder carcinoma - the first phase I/IIa trial. Clin Cancer Res 16:3279-3287
6. Vardouli L, Lindqvist C, Vlahou K, Loskog AS, Eliopoulos AG (2009) Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Cancer Gene Ther 16:848-860
7. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323 (Pubitemid 27114163)
8. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP et al (1999) Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 59:325-330 (Pubitemid 29048862)
9. Sachs MD, Rauen KA, Ramamurthy M, Dodson JL, De Marzo AM, Putzi MJ et al (2002) Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology 60:531-536 (Pubitemid 35292199)
10. Maitland N, Chambers K, Georgopoulos L, Simpson-Holley M, Leadley R, Evans H et al (2010) Clinical adenoviral gene therapy for prostate cancer. Hum Gene Ther 21:807-813
11. Siefker-Radtke A (2010) Bladder cancer: can we move beyond chemotherapy? Curr Oncol Rep 12:278-283
12. Gaggar A, Shayakhmetov DM, Lieber A (2003) CD46 is a cellular receptor for group B adenoviruses. Nat Med 9:1408-1412 (Pubitemid 37466191)
13. Ganesh S, Gonzalez Edick M, Idamakanti N et al (2007) Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res 67:4399-4407 (Pubitemid 46815089)
14. Yu L, Takenobu H, Shimozato O et al (2005) Increased infectivity of adenovirus type 5 bearing type 11 or type 35 fibers to human esophageal and oral carcinoma cells. Oncol Rep 14:831-835
15. Hoffmann D, Meyer B, Wildner O (2007) Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses. J Gene Med 9:764-778 (Pubitemid 47386861)
16. Hoffmann D, Heim A, Nettelbeck DM et al (2007) Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma. Hum Gene Ther 18:51-62 (Pubitemid 46105464)
17. Lindqvist C, Sandin LC, Fransson M, Loskog A (2009) Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition. J Immunother 32:785-792
18. He XD, Wang ZP, Wei HY, Zhou Q, Wang DG, Tian JQ et al (2009) Construction of urothelium-specific recombinant adenovirus and its inhibition in bladder cancer cell. Urol Int 82:209-213
19. Wu CL, Shieh GS, Chang CC, Yo YT, Su CH, Chang MY et al (2008) Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models. Clin Cancer Res 14:1228-1238
20. Terao S, Shirakawa T, Kubo S, Bishunu A, Lee SJ, Goda K et al (2007) Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model. Urology 70:1009-1013 (Pubitemid 350192581)
21. Gomella LG, Mastrangelo MJ, McCue PA, Maguire HC Jr, Mulholland SG, Lattime EC (2001) Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol 166:1291-1295 (Pubitemid 32862158)
22. Rein DT, Breidenbach M, Kirby TO, Han T, Siegal GP, Bauerschmitz GJ et al (2005) A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 11:1327-1335 (Pubitemid 40175787)
23. Lu ZZ, Ni F, Hu ZB, Wang L, Wang H, Zhang QW et al (2006) Efficient gene transfer into hematopoietic cells by a retargeting adenoviral vector system with a chimeric fiber of adenovirus serotype 5 and 11p. Exp Hematol 34:1171-1182
24. He X, Liu J, Yang C, Su C, Zhou C, Zhang Q, et al (2011) 5/35 Fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells. Hum Gene Ther 22:283-292
25. Toyoda E, Doi R, Kami K, Mori T, Ito D, Koizumi M et al (2008) Adenovirus vectors with chimeric type 5 and 35 fiber proteins exhibit enhanced transfection of human pancreatic cancer cells. Int J Oncol 33:1141-1147
26. Yu L, Shimozato O, Li Q, Kawamura K, Ma G, Namba M et al (2007) Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. Anticancer Res 27:2311-2316 (Pubitemid 47228069)
27. Ma L, Liu J, Shen J, Liu L, Wu J, Li W et al (2010) Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther 9:554-561